|1.||Gaudiano, Giorgio: 1 article (01/2002)|
|2.||Cogan, Peter: 1 article (01/2002)|
|3.||Powers, Barbara E: 1 article (01/2002)|
|4.||Taatjes, Dylan J: 1 article (01/2002)|
|5.||Koch, Tad H: 1 article (01/2002)|
|6.||Dernell, William S: 1 article (01/2002)|
|7.||Koch, T H: 1 article (01/2001)|
|8.||Taatjes, D J: 1 article (01/2001)|
01/01/2002 - "Epidoxoform appears to be efficacious in this model of mammary carcinoma, with improved efficacy over the parent compound epidoxorubicin. "
01/01/2002 - "This study was conducted to evaluate the toxicity and efficacy of Epidoxoform, a prodrug of the active metabolite of epidoxorubicin, in a mouse model of mammary carcinoma. "
01/01/2002 - "Evaluation of the epidoxorubicin--formaldehyde conjugate, epidoxoform, in a mouse mammary carcinoma model."
01/01/2002 - "In all efficacy trials, a significant difference was found for tumor volume between Epidoxoform and epidoxorubicin treated mice and controls. "
01/01/2002 - "Two days following injection of 10(6) Gollin-B mouse mammary tumor cells into the mammary fat pad, Epidoxoform was given and tumor growth compared to mice treated similarly with the maximum tolerated dose of epidoxorubicin and untreated controls. "
01/01/2001 - "The results of the lead conjugate, Epidoxoform, in the National Cancer Institute 60 human tumor cell screen are presented and discussed in terms of some resistance mechanisms. "
04/09/1998 - "Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells."
07/01/1999 - "Synthetic formaldehyde conjugates of DOX, DAU, and EPI, denoted Doxoform (DOXF), Daunoform (DAUF), and Epidoxoform (EPIF), exhibit enhanced toxicity to anthracycline-sensitive and -resistant tumor cells. "
|3.||Breast Neoplasms (Breast Cancer)
04/09/1998 - "Epidoxoform and epidoxorubicin plus formaldehyde react with the self-complementary DNA octamer (GC)4 to yield five drug-DNA adducts which have structures analogous to the doxorubicin-DNA adducts from reaction of Doxoform with (GC)4. Epidoxoform is 3-fold more toxic to MCF-7 human breast cancer cells and greater than 120-fold more toxic to MCF-7/ADR resistant cells than epidoxorubicin. "
|5.||Complementary DNA (cDNA)